In Silico Identification of Novel Drug Targets for Campylobacter Jejuni and Potential Drug Molecules

Abstract

Campylobacter jejuni is the main responsible organism of Campylobacteriosis, a diarrhoea-like condition involving symptoms like nausea, vomiting, enteralgia and, in critical cases, reactive arthritis and Guillain-Barré syndrome. Usually, this disease is treated without antibiotics, but antibiotic therapy is important for patients with severe sickness as well as post-infection problems. Campylobacter is a gram-negative bacterium that has acquired antibiotic resistance due to drug overuse and misuse, which has led to a search for new antibiotics against C. jejuni, as it continues to remain untreated with the already available drugs on the market, like, Azithromycin, Erythromycin, Ciprofloxacin, Tetracycline, etc. The search for new antibiotics is carried out with the help of Computer-Aided Drug Discovery, a computational technology for discovering new drugs targeting various medicinal targets or virulence factors of C. jejuni.